Zhijian Life Secures Tens of Millions in Pre-A Financing to Accelerate AI-Powered Medical Diagnostic Solutions

On August 3, 2023, Chongqing Zhijian Life Technology Co., Ltd. and Yangming Capital held a financing signing ceremony at the Jinfeng Laboratory in Chongqing.ZHIJIAN LIFE Completes RMB 10 Million Pre-A Financing Round, Led by Yangming Capital, a Venture Capital Sub-Fund of the National Fund for Technology Transfer and Commercialization. The Funds Will Be Primarily Used for the Research and Development of Informatics and Intelligent Products for Pathology Departments, Accelerating Industry Application Deployment.

Zhao Chaoming, Chairman of Yangming Capital; Li Changde, President of Yangming Capital; Cui Hongliang, CEO of ZHIJIAN LIFE; Kong Xiangbing, COO of ZHIJIAN LIFE; Xu Hui, Deputy Director of Jinfeng Laboratory; Xu Yi, Minister of Strategic Planning Department of Jinfeng Laboratory; and other leaders from Jinfeng Laboratory attended the ceremony.

ZHIJIAN LIFE is dedicated to“Digital Pathology” Key Information System Platform Construction: Enabling Next-Generation Precision Pathological Diagnosis.

The core team brings together talent from interdisciplinary fields, including high-performance computing, bioinformatics, image processing, artificial intelligence, and big data. In collaboration with experts in pathology and oncology from China’s top-tier Grade 3A hospitals, the team jointly develops an integrated AI-assisted diagnostic solution and product suite that combines medical imaging, pathology, and omics. This initiative delivers advanced, intelligent services and products to healthcare institutions, physicians, patients, and academic research organizations, thereby driving technological transformation through the convergence of high-performance computing and biomedical big data, as well as promoting the industrial upgrading of smart healthcare.

The level of development and construction in clinical pathology is a key indicator of national healthcare quality and determines the sustainable advancement of the medical field. Currently, medicine has entered a new era of holistic health and precision medicine. Traditional histopathology is rapidly evolving into “Next-Generation Diagnostic Pathology,” characterized by multimodal big data integration and comprehensive diagnosis that combines morphological assessment, molecular testing, bioinformatics analysis, and artificial intelligence–assisted interpretation.

With pathological diagnosis as the entry point, ZHIJIAN LIFE has comprehensively promoted the construction of key information system platforms for “digital pathology” within less than three years of its establishment, addressing the major bottlenecks facing China’s traditional pathology industry, namely “staff shortages, heavy workloads, and high demands.”, forming a suite of products including the Standardized Training and Teaching System for Pathology, the Digital Pathology Image Transmission and Standardized Archiving System (DPACS), and the CNAS-Visualized Analytics System (CNAS-VAS) for intelligent supervision of digital pathology laboratories. These efforts gradually establish a modern pathology department characterized by informatization, digitalization, and standardization. By exerting multi-perspective, multi-level, and comprehensive efforts in areas such as standardized residency training for pathologists, CNAS accreditation, laboratory management, quality control, and the digitalization and standardization of pathological images, the company optimizes talent development mechanisms and enhances the automation and digitalization levels of pathology departments.

Pathology is a vital component of multidisciplinary team (MDT) consultations. The integration of digital pathology, smart pathology, and integrated diagnostics has emerged as a new trend driving the advancement of pathological diagnosis.

ZHIJIAN LIFE leverages the strengths of its R&D team, which features deep integration across interdisciplinary fields such as high-performance computing, biomedicine, image processing, artificial intelligence, and big data.Developed multiple key technologies and products for non-invasive, AI-assisted diagnosis based on multimodal (imaging and molecular) data fusion and the integration of imaging with pathology; established comprehensive clinical decision-support technologies and system solutions for the entire tumor care pathway, leveraging medical-specific large language models.The product portfolio covers multiple cancer types, including lung cancer, breast cancer, brain tumors, and bladder cancer. The company has successively developed several products and solutions, such as an intelligent intraoperative frozen section diagnosis system, a multimodal data-fusion AI-assisted diagnostic system for brain tumors, a high-throughput integrated intelligent analysis platform for multimodal bioinformatics, an AI-assisted predictive diagnostic system for pneumonia based on imaging and pathology (iPaid), and a full-process auxiliary decision-making solution for chronic kidney disease. By integrating the entire pathological diagnosis workflow—comprising scanning (digital scanning), storage, management, application (intelligent AI-assisted diagnosis), and translation (industrialization)—the company accelerates the standardization and digitalization of the AI pathology ecosystem.

In addition, as a professional service provider with long-term vision,In the future, ZHIJIAN LIFE will continue to meet the informatization, digitalization, and intelligence needs of pathology departments and other clinical specialties, constantly expand its product pipeline, and bring more advanced technologies and services to the market and customers. This will accelerate the informatization and intelligent transformation of pathology departments and other medical specialties in China, contributing to the high-quality development of China’s healthcare industry.

ZHIJIAN LIFE focuses on big data technologies in pathological medicine and artificial intelligence (AI)-based diagnostic technologies, providing key information system platforms for “digital pathology” as well as AI-assisted medical diagnostic solutions and product services to major healthcare institutions across society. This accelerates the transition of pathological diagnosis toward “next-generation diagnostic pathology.” Through independent research and development, its core technologies and products have deeply empowered more than 50 Grade A tertiary hospitals and medical institutions, facilitating the integration of advanced diagnostic technologies and products into the healthcare system.

Fujian Yangming Capital is a specialized investment institution focused on biotechnology, pharmaceuticals, healthcare, and the broader health sector. With extensive investment management experience and a broad resource network, Yangming Capital has successfully invested in numerous pharmaceutical and healthcare projects. The firm excels in project evaluation and post-investment management, and is committed to identifying and nurturing high-potential technology-driven innovative enterprises to advance technological innovation and industrial development.